A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of KBP-5074 Mineralocorticoid Receptor Antagonist in Subjects With Uncontrolled Hypertension and Moderate or Severe (Stage 3b/4) CKD

This Phase 3, randomized, Double-blind, placebo-controlled, 2-arm, parallel-group, multicenter study with randomized withdrawal will evaluate the efficacy, safety, and durability of KBP-5074 in adult participants who have stage 3b/4 chronic kidney disease (CKD) (estimated glomerular filtration rate [eGFR] calculated using the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula [eGFR {EPI}] ≥15 to ≤44 mL/min/1.73 m^2) and uncontrolled hypertension (systolic blood pressure (SBP) ≥140 and <180 mm Hg and taking 2 or more antihypertensive medications.

开始日期2021-11-05

申办/合作机构

KBP Biosciences USA, Inc.

NCT04634812

/ Completed临床1期

A Phase 1, Open-label, Study of the Absorption, Metabolism, and Excretion of [14C]-KBP-5074 Following a Single Oral Dose in Healthy Male Subjects

This is a Phase 1, open-label, nonrandomized, single-dose mass balance and metabolite identification study in healthy male subjects.

开始日期2020-12-03

申办/合作机构

KBP Biosciences USA, Inc.

[+1]

NCT04606537

/ Completed临床1期

Phase 1, Open-label, Parallel, 2-arm, Fixed-sequence Study to Investigate the Effect of Coadministration of CYP3A4 Inhibitor and CYP3A4 Inducer on the Pharmacokinetics, Safety, and Tolerability of KBP-5074 in Healthy Subjects

Open-label, parallel, 2-arm, fixed-sequence study to investigate the effect of coadministration of a CYP3A4 inhibitor (Cohort 1, itraconazole multiple dose) and CYP3A4 inducer (Cohort 2, rifampin multiple dose) on the plasma PK of a single dose of KBP-5074 in healthy male and female subjects.

开始日期2020-10-24

申办/合作机构

KBP Biosciences USA, Inc.

[+1]

100 项与阿莫奎尼相关的临床结果

登录后查看更多信息

100 项与阿莫奎尼相关的转化医学

登录后查看更多信息

100 项与阿莫奎尼相关的专利（医药）

登录后查看更多信息

项与阿莫奎尼相关的文献（医药）

2025-05-01·CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION

Targeting aldosterone to improve cardiorenal outcomes: from nonsteroidal mineralocorticoid receptor antagonists to aldosterone synthase inhibitors

Review

作者: Hundemer, Gregory L. ; Helmeczi, Wryan

Purpose of review:

Aldosterone dysregulation plays a major role in the pathogenesis of hypertension, cardiovascular disease, and kidney disease. Traditionally, steroidal mineralocorticoid receptor (MR) antagonists, namely spironolactone and eplerenone, have been the only available options to target aldosterone. Over recent years, a host of promising novel aldosterone-targeted pharmacologic agents have been developed thereby providing new options to mitigate aldosterone-mediated cardiovascular and kidney disease.

Recent findings:

Recently, a number of nonsteroidal MR antagonists (finerenone, esaxerenone, and ocedurenone) and highly specific aldosterone synthase inhibitors (baxdrostat, lorundrostat, dexfadrostat, and vicadrostat) have been developed. The early clinical data for these novel medications looks promising regarding their efficacy in improving blood pressure control, preventing adverse cardiovascular outcomes, and slowing chronic kidney disease progression. Moreover, they appear to be generally safe and well tolerated.

Summary:

In the coming years, nonsteroidal MR antagonists and aldosterone synthase inhibitors are likely to play an increasingly large role in routine medical practice to help improve cardiovascular and kidney outcomes.

2025-03-01·Nefrologia

Evidence for the use of a nonsteroidal mineralocorticoid receptor antagonist for the treatment of chronic kidney disease

Review

作者: Avito Fernandes de Almeida, Edgar ; Marques da Silva, Bernardo ; Morais David Pliças, Mariana

INTRODUCTION AND OBJECTIVES:

Chronic kidney disease morbimortality drives the development of new drugs. This work summarizes the evidence on the use of non-steroidal mineralocorticoid receptor antagonists on chronic kidney disease.

MATERIALS AND METHODS:

A search was performed on PubMed and ClinicalTrials.gov using relevant keywords for clinical trials and observational studies, finished or ongoing, from 2019 to 2023.

RESULTS:

Finerenone is currently approved for diabetic kidney disease with albuminuria, with results from two phase three trials, presenting satisfactory results on renal and cardiovascular outcomes and an appropriate safety profile, namely regarding potassium balance. Regarding nondiabetic kidney disease, combining sodium glucose transport protein-2 inhibitors and finerenone points toward reliable results, although these came from non-placebo-controlled trials. An ongoing phase three trial is assessing finerenone efficacy and safety on nondiabetic chronic kidney disease. Esaxerenone is approved for diabetic nephropathies and hypertension in Japan, based on two phase three clinical trials. These trials' external validity is compromised, as they were only developed in Japan. Ocedurenone presents results from a phase two trial on managing refractory hypertension on chronic kidney disease. Apararenone is being investigated for diabetic kidney disease, with results from a phase two study, limited for only including Japanese patients.

CONCLUSIONS:

With this review we provide a global perspective on the available clinical results for these drugs to improve its evidence-based use.

2024-11-01·Heart (British Cardiac Society)

Diagnosis and management of resistant hypertension

Review

作者: Kreutz, Reinhold ; Cho, Myeong-Chan ; Camafort, Miguel

Resistant hypertension is a condition where blood pressure levels remain elevated above target despite changes in lifestyle and concurrent use of at least three antihypertensive agents, including a long-acting calcium channel blocker (CCB), a blocker of the renin-angiotensin system (ACE inhibitor or angiotensin receptor blocker) and a diuretic. To be diagnosed as resistant hypertension, maintaining adherence to therapy is required along with confirmation of blood pressure levels above target by out-of-office blood pressure measurements and exclusion of secondary causes of hypertension. The key management points of this condition include lifestyle changes such as reduced sodium and alcohol intake, regular physical activity, weight loss and discontinuation of substances that can interfere with blood pressure control. It is also recommended that current treatment be rationalised, including single pill combination treatment where antihypertensive drugs should be provided at the maximum tolerated dose. It is further recommended that current drugs be replaced with a more appropriate and less difficult treatment regimen based on the patient’s age, ethnicity, comorbidities and risk of drug–drug interactions. The fourth line of treatment for patients with resistant hypertension should include mineralocorticoid receptor antagonists such as spironolactone, as demonstrated in the PATHWAY-2 trial and meta-analyses. Alternatives to spironolactone include amiloride, doxazosin, eplerenone, clonidine and beta-blockers, as well as any other antihypertensive drugs not already in use. New approaches under research are selective non-steroidal mineralocorticoid receptor antagonists such as finerenone, esaxerenone and ocedurenone, selective aldosterone synthase inhibitors such as baxdrostat, and dual endothelin antagonist aprocitentan.

项与阿莫奎尼相关的新闻（医药）

2025-10-17

·FiercePharma

Fierce Pharma Asia—High-dollar licensing deals; Takeda's AI drug design pact; and the finale of Novo vs. KBP

Licensing deals featuring China biotechs, an AI drug design pact and Chapter 3 of the deep dive into Novo Nordisk versus KBP Biosciences made our news this week. Dianthus Therapeutics and Boehringer Ingelheim headlined the latest round of licensing deals featuring Chinese biotechs. Fierce's deep dive into the dispute between Novo Nordisk and KBP Biosciences wrapped up with Chapter 3. Takeda inked its second pact with Nabla Bio. And more.1. Dianthus offers up to $1B for China biotech's autoimmune 'pipeline in a product'New York City-based Dianthus Therapeutics has scoped out a first-in-class asset with best-in-class potential in Nanjing Leads Biolabs’ LBL-047. In a deal worth up to $1 billion, Dianthus has picked up ex-China rights to the drug candidate, which is now dubbed DNTH212. The drug, a bifunctional BDCA2 and BAFF/APRIL inhibitor, is designed to block two clinically validated pathways that are known drivers of several autoimmune diseases, according to Dianthus.2. Novo vs. KBP Chapter 3: Fraud or due diligence slipup?Fierce’s deep dive into the dispute between pharma giant Novo Nordisk and Singapore biotech upstart KBP Biosciences concluded with Chapter 3, which examined the arguments around due diligence that went into the ill-fated drug acquisition. While Novo maintains that KBP failed to disclose certain material information about its hypertension drug hopeful ocedurenone, KBP hit back by saying Novo failed to properly look into the acquisition and that the biotech didn’t have a duty to share more information. Fierce’s Angus Liu interviewed several experts who are not parties to the dispute to gain third-party perspectives. 3. Boehringer Ingelheim digs in on ADCs, offering up to $991M to license cancer prospect from Korea's AimedBioIt wasn’t only Dianthus tapping innovation out of Asia this week. In a deal worth up to $991 million, Boehringer Ingelheim is getting in on an antibody-drug conjugate from South Korea’s AimedBio. The candidate is expected to enter first-in-human testing next year. The preclinical ADC weds a cancer-targeting monoclonal antibody with a derivative of exatecan as the cytotoxic payload. For Boehringer, the deal follows a pair of other plays in the ADC space this year.4. Takeda turns to AI drug designer for $1B biobucks deal after whittling down R&D focusArtificial intelligence drug design and discovery deals are continuing apace in the industry, with Japanese pharma giant Takeda this week inking its second pact with Nabla Bio. A spinout from the lab of George Church, Ph.D., Nabla is in line to receive “double-digit millions in upfront and research cost payments,” according to a press release. Nabla attracted the attention of several pharma giants last year when it unveiled its first Takeda collab alongside deals with AstraZeneca and Bristol Myers Squibb.5. Senate endorses Biosecure Act successor, adopting softer tone and omitting WuXi companiesAfter last year's Biosecure Act prompted serious industry concerns, the U.S. Senate has passed a new version of the legislation as an amendment to the National Defense Authorization Act. The legislation broadly seeks to prevent any Chinese biopharma "company of concern" from receiving U.S. federal funding, either directly or through intermediary companies. Notably, the new version doesn’t name two key biopharma industry partners in WuXi Biologics and WuXi AppTec. The U.S. House of Representatives would need to pass its own version of the legislation before it could go before President Donald Trump for a potential signature.Other News of Note:6. Singapore-based CytoMed bids on 'potentially synergistic assets' from TC BioPharm (Release)

引进/卖出抗体药物偶联物

2025-10-10

·FiercePharma

Fierce Pharma Asia—TROP2 showdown; InnoCare, Zenas' $2B autoimmune deal; Lupin's US investment

Datroway's phase 3 triple-negative breast cancer win, InnoCare Pharma and Zenas BioPharma's autoimmune licensing deal and Lupin's planned investment in Florida made our news this week. AstraZeneca and Daiichi Sankyo are teeing up a TROP2 showdown with Gilead Sciences in first-line triple-negative breast cancer. China's InnoCare Pharma agreed to out-license three autoimmune candidates to Zenas BioPharma. Lupin plans to invest $250 million to build a new plant in Florida. And more.1. AZ, Daiichi score 'landmark' results for ADC Datroway in triple-negative breast cancerAstraZeneca and Daiichi Sankyo said their TROP2 antibody-drug conjugate Datroway extended overall survival against chemotherapy when used as a treatment for first-line triple-negative breast cancer in patients who are not up for immunotherapy. The phase 3 Tropion-Breast02 win sets up likely competition with Gilead Sciences' Trodelvy, which is not yet able to tout an overall survival benefit from its own Ascent-03 trial.2. Zenas makes big bet on MS drug, striking $2B licensing deal with InnoCareZenas BioPharma has signed a licensing deal to obtain three autoimmune disease assets from China’s InnoCare Pharma. For $100 million upfront and near-term milestone payments, Zenas gained development and commercial rights to orelabrutinib in multiple sclerosis globally and in non-oncology indications in certain territories. The drug is approved in China for the treatment of certain blood cancers. The potential $2 billion deal also includes an IL-17AA/AF inhibitor and a TYK2 inhibitor.3. Lupin rides the onshoring wave, pledging $250M to build new respiratory production plant in Fla.Lupin plans to build a new manufacturing plant in Coral Springs, Florida, with capacity to produce more than 25 critical respiratory medicines. The Indian pharma expects to invest $250 million across R&D, infrastructure and capital expenditures at the site over five years. The company has acquired more than five acres of land to construct the planned 70,000-square-foot site.4. Novo vs. KBP Chapter 2: 'Anomalous' trial resultsThe second chapter of Fierce Biotech's deep dive into the showdown between Novo Nordisk and KBP Biosciences focuses on the outsized treatment effect observed at a Bulgaria site in both the phase 2 and phase 3 trials of ocedurenone. Novo alleged that the “anomalous” data were indication of possible fraud, while KBP argued that Novo was trying to obtain worse clinical outcomes to allegedly cover up its own wrong decision to terminate the program.5. Expedition resupplies for phase 2 COPD voyage with $165M series AExpedition Therapeutics, which is built on a model of in-licensing drugs from China, has raised $165 million in a series A round led by Sofinnova Investments and Novo Holdings. The proceeds will go toward a global phase 2 study for the biotech’s lead candidate, EXPD-101, in chronic obstructive pulmonary disease. Expedition got the DPP1 inhibitor from Fosun Pharma.6. Eli Lilly earmarks $1B-plus for contract manufacturing partnerships in IndiaEli Lilly plans to invest more than $1 billion in contract manufacturing partnerships in India. The investment will help boost the supply of the Illinois pharma’s drugs for obesity, diabetes, Alzheimer’s disease, cancer and autoimmune conditions through local manufacturers. Part of the investment will be used on a facility in Hyderabad to oversee the local network of contractors.Other News of Note:7. Ono's BMS-partnered EP4 antagonist improves progression-free survival in phase 2 gastric cancer test8. FDA launches generics pilot program, advances facility PreCheck proposal in bid to incentivize US drug manufacturing9. Trump excludes generics from Big Pharma tariff plan (The Wall Street Journal)10. AviadoBio secures option to rare eye disease gene therapy that could bring Chinese biotech $413M11. Olympus, W.L. Gore link on global distribution deal for endoscopic placement tool12. Lotus signs semaglutide generic deal with Adalvo (release)

引进/卖出临床2期临床3期免疫疗法基因疗法

2025-08-24

·研发客

除了首付款，BD 交易还需关注哪些条款？

// • 中国Biotech在BD交易中存在“重商业、轻法律”倾向，易忽略潜在风险； • 中国公司参与的BD交易合同多遵循英美法，“商业合理努力”判定是争议焦点； • 里程碑完成标准是BD交易重要条款，合同中仅泛泛规定容易引发争议； • 中国Biotech要有从“签合同”到“管合同”的全流程意识。近年来，中国创新药公司与跨国药企的license交易如火如荼，但背后的法律风险却鲜少被深入讨论。今年上半年，诺和诺德起诉亨利医药索赔60亿元人民币的事件，正在露出其中的冰山一角。这起事件固然涉及商业道德、信息披露机制等，同时也在提示中国创新药公司，在BD交易的过程中，除了首付款、后续联合开发之外，还有更多法律方面的细节需要留意。风险点隐藏在被忽视的条款中通过与MNC的授权合作，中国公司渡过资本寒冬，解现金流“燃眉之急”。也正因如此，这些被资本裹挟着前进的企业，在BD交易的过程中，把更多注意力聚焦在预付款上。富而德律师事务所资深法律顾问马娅观察到这一现象。过去几年，她参与了多起中国药企license out的交易，在欣喜地看到中国药企谈判地位大幅提升的同时，发现部分中国药企在交易谈判过程中非常重视预付款，却并不在意后续里程碑款项是否能兑现而可能产生的违约或合同纠纷。她对这种“重商业、轻法律”的做法感到担忧。富而德律师事务所资深法律顾问马娅 “由于急于促成交易，中国Biotech往往忽略了交易文件中的很多法律条款，包括从律师角度来看的一些潜在风险。在一些交易金额较大的BD项目中，仅由BD团队牵头谈判，内部法务及外部律师参与的部分很有限。但其实BD交易中商业条款和法律条款互相勾连，其中的风险点很容易被漏掉。”马娅说。如何判定“商业合理努力” 据马娅介绍，中国公司参与的BD交易合同文本多遵循英美法，也沿用英美国家惯常使用的合同模板。但很多中国公司并未意识到的是，英美是判例法国家，英美法下的合同模板，其中条款措辞的细微差异就可能导致完全不同的法律后果，这与中国的法律体系差异很大。 “比如一家中国生物医药公司，把一款临床Ⅱ期产品权益license给MNC。中国公司继续在国内完成Ⅲ期试验并申请上市，MNC在境外开展临床。在这样一个架构中，交易文本中会明确license许可方（即中国公司）要尽商业合理努力继续完成临床试验，申请上市。对于如何判定许可方已经作出了‘商业合理努力’，在交易谈判和合同实施过程中，都是争议的焦点。” “在美国法下，不同的尽职义务，包括‘最大努力’‘合理努力’‘商业合理努力’的涵义，其实是有很多判例法来支持的。实践中较多采纳‘商业合理努力’的概念。” “但是，一个BD项目最终未能成功的因素可能有很多。那么，在哪些情况下项目未能成功或按时完成是因为许可方未能尽到‘合理商业努力’造成的，就需要双方在合同条款里作出详细的约定。比如在协议实施过程中，许可方还有其他的管线产品，他把资源先用在其他管线上，没有放在标的许可产品里，这算不算没有履行尽职义务？配备多少人员、花多少时间是按照Biotech自己的标准，还是MNC的标准，还是行业惯例？按行业惯例判断的话，是中国的行业惯例还是美国行业惯例？这些都需要事先有所约定以避免未来出现分歧。” 里程碑的完成标准也是BD交易里的重要条款。比如，很多合同里只是泛泛地写了“取得中国监管部门的上市许可”作为里程碑付款的条款，但实践中还有很多细节需要明确。比如上市许可批准的什么适应症，附条件的许可算不算符合条件等，如果不能明确一个非常具体的无争议的标准，实践中很容易出现争议。未来几年法律风险可能浮出水面今年2月，诺和诺德将昔日的授权合作方亨利医药送上被告席，指控后者及其创始人黄振华涉嫌故意未披露药物试验中的重大不利信息，并索赔8.3亿美元。双方的合作追溯到2023年10月，当时，诺和诺德以总价13亿美元从亨利医药手中买下一款治疗肾病高血压在研产品 Ocedurenone（KBP-5074）。意想不到的是，2024年6月，诺和诺德宣布该产品Ⅲ期临床试验中期分析研究没有达到主要终点，并停掉该管线的后续研发工作。诺和诺德方面认为，亨利医药隐瞒 Ocedurenone 的Ⅱ期试验结果中期分析数据，给公司带来了超过 8 亿美元的损失。诺和诺德起诉亨利医药在尽调过程当中，隐瞒了一些对公司不利的临床试验数据。这也是中国公司可能忽略的问题。由于文化上的差异加上急于达成交易，中国公司可能会隐瞒一些对自己不利的数据，这可能是未来一个潜在的纠纷点。这两年，中国Biotech公司与MNC快速达成了大量的交易，而未来2~3 年将是milestone的“临近期”，届时可能会有一些纠纷逐渐出现。企业需要非常冷静的思考一下，从法律的角度会有哪些风险，以及出现这些风险之后怎么去应对。从“签合同”到“管合同”的全流程意识从律师的角度来看，马娅观察到，很多中国企业急于签署合同后马上推进后续工作，而具体实施合同的团队并不是合同谈判的团队，加上实施合同的人员对于合同条款并没有深入的理解，这就很容易导致合同的执行和合同条款的脱节。她认为，如果中国的生物医药公司真正瞄准出海国际化，一定要重视法律文本里面的约定。尽早在合同谈判的过程当中，把一些漏洞堵住，不要等到未来出现纠纷再去解决。在合同签署和执行的过程中，寻求专业人士的指导，帮助理解和梳理具体的合同条款和各方的合同义务。公司需要明确理解，这些条款对于自己意味着什么，并且在执行中严格遵守合同的约定。如果产品开发上市过程一切顺利，一个BD交易的合同通常有10~20年的周期，这期间很有可能出现新的情况和变化，导致原合同的条款不再适用甚至出现不合规的情况。比如，在合同签署时，双方并不属于竞争对手地位，因此约定不竞争条款的合规风险并不高；但随着时间推移，双方变成竞争对手了，合同中的不竞争条款可能会有违反反垄断法的风险，这个时候需要及时与对方谈判变更、修订。编辑 | 毛冬蕾 Mao.Donglei@PharmaDJ.com 总第2548期访问研发客网站，深度报道和每日新闻抢鲜看 www.PharmaDJ.com

引进/卖出临床3期临床2期

100 项与阿莫奎尼相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性肾病	临床3期	美国	KBP Biosciences USA, Inc.	2021-11-05
慢性肾病	临床3期	中国	KBP Biosciences USA, Inc.	2021-11-05
慢性肾病	临床3期	澳大利亚	KBP Biosciences USA, Inc.	2021-11-05
慢性肾病	临床3期	波斯尼亚和黑塞哥维那	KBP Biosciences USA, Inc.	2021-11-05
慢性肾病	临床3期	保加利亚	KBP Biosciences USA, Inc.	2021-11-05
慢性肾病	临床3期	加拿大	KBP Biosciences USA, Inc.	2021-11-05
慢性肾病	临床3期	克罗地亚	KBP Biosciences USA, Inc.	2021-11-05
慢性肾病	临床3期	捷克	KBP Biosciences USA, Inc.	2021-11-05
慢性肾病	临床3期	格鲁吉亚	KBP Biosciences USA, Inc.	2021-11-05
慢性肾病	临床3期	德国	KBP Biosciences USA, Inc.	2021-11-05

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04968184 (CLARION-CKD, NEWS) 人工标引	临床3期	高血压 \| 慢性肾病	600	ocedurenone	淵鏇窪範窪繭齋鬱網鹹(觸夢餘顧窪壓鬱鑰餘簾) = failed to meet its primary endpoint 願顧鏇顧廠鬱衊網窪廠 (願選窪簾製醖鏇顧醖鹹 ) 未达到	不佳	2024-06-27
NCT04534699 (KBP-5074, Pubmed \| Eur J Drug Metab Pharmacokinet)	临床1期	肝功能不全	-	Ocedurenone 0.5 mg	鏇願廠糧觸範獵糧糧窪(願齋壓糧繭齋網繭艱鑰) = 糧夢衊鏇簾糧製蓋鑰壓構齋遞顧鏇構構齋糧衊 (觸鏇淵網範獵窪淵網壓 ) 更多	-	2024-03-01
				Placebo	鏇願廠糧觸範獵糧糧窪(願齋壓糧繭齋網繭艱鑰) = 窪鹹製憲齋衊願築衊膚構齋遞顧鏇構構齋糧衊 (觸鏇淵網範獵窪淵網壓 ) 更多
NCT03574363 (BLOCK-CKD, Pubmed \| Hypertension)	临床2期	慢性肾病	162	Placebo	繭淵窪衊網窪齋醖築鹽(製鹽簾襯襯淵積繭遞鬱) = 網簾觸鏇廠積築鏇餘鹹膚簾鹹夢鑰淵網壓觸鬱 (襯觸糧醖淵餘遞鑰鑰蓋 )	积极	2021-07-01
				KBP-5074 0.25 mg	繭淵窪衊網窪齋醖築鹽(製鹽簾襯襯淵積繭遞鬱) = 壓繭鏇築夢簾鏇壓製夢膚簾鹹夢鑰淵網壓觸鬱 (襯觸糧醖淵餘遞鑰鑰蓋 )
NCT02837237 (CTgov)	临床1期	终末期肾脏病 \| 慢性肾病	11	KBP-5074	鬱構淵襯鏇鑰築顧顧齋 = 艱構壓鹽築網選夢製蓋獵築顧膚艱憲餘夢淵鹹 (壓積艱醖積鏇繭顧鑰願, 壓齋膚艱夢餘壓壓範餘 ~ 廠範鹽鑰鬱蓋淵簾獵範) 更多	-	2019-10-15
Phase 1 (ASN2017)	临床1期	慢性肾病	11	KBP-5074 0.5 mg	積夢願糧襯淵襯鏇艱網(鹹獵膚夢鏇膚鹹廠糧簾) = 網襯構積襯餘簾衊醖壓積積選網製醖膚糧簾顧 (壓範淵鬱膚願鹽製淵觸 ) 更多	积极	2017-10-31
				KBP-5074 (Hemodialysis)	積夢願糧襯淵襯鏇艱網(鹹獵膚夢鏇膚鹹廠糧簾) = 獵範廠淵鹹構壓餘遞網積積選網製醖膚糧簾顧 (壓範淵鬱膚願鹽製淵觸 ) 更多